International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(18), P. 9778 - 9778
Published: Sept. 10, 2024
Like
most
tumors,
glioblastoma
multiforme
(GBM),
the
deadliest
brain
tumor
in
human
adulthood,
releases
extracellular
vesicles
(EVs).
Their
content,
reflecting
that
of
origin,
can
be
donated
to
nearby
and
distant
cells
which,
by
acquiring
it,
become
more
aggressive.
Therefore,
study
EV-transported
molecules
has
very
important.
Particular
attention
been
paid
EV
proteins
uncover
new
GBM
biomarkers
potential
druggable
targets.
Proteomic
studies
have
mainly
performed
“bottom-up”
mass
spectrometry
(MS)
analysis
EVs
isolated
different
procedures
from
conditioned
media
cultured
biological
fluids
patients.
Although
a
great
number
dysregulated
identified,
translation
these
findings
into
clinics
remains
elusive,
probably
due
multiple
factors,
including
lack
standardized
for
isolation/characterization
their
proteome.
Thus,
it
is
time
change
research
strategies
adopting,
addition
harmonized
selection
techniques,
MS
methods
aimed
at
identifying
selected
tumoral
protein
mutations
and/or
isoforms
post-translational
modifications,
which
deeply
influence
behavior.
Hopefully,
data
integrated
with
those
other
“omics”
disciplines
will
lead
discovery
pathways
novel
therapies.
CA A Cancer Journal for Clinicians,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 22, 2025
Abstract
Next‐generation
sequencing
has
revealed
the
disruptive
reality
that
advanced/metastatic
cancers
have
complex
and
individually
distinct
genomic
landscapes,
necessitating
a
rethinking
of
treatment
strategies
clinical
trial
designs.
Indeed,
molecular
reclassification
cancer
suggests
it
is
underpinnings
disease,
rather
than
tissue
origin,
mostly
drives
outcomes.
Consequently,
oncology
trials
evolved
from
standard
phase
1,
2,
3
tissue‐specific
studies;
to
tissue‐specific,
biomarker‐driven
trials;
tissue‐agnostic
untethered
histology
(all
drug‐centered
designs
);
and,
ultimately,
patient‐centered
,
N‐of‐1
precision
medicine
studies
in
which
each
patient
receives
personalized,
biomarker‐matched
therapy/combination
drugs.
Innovative
technologies
beyond
genomics,
including
those
address
transcriptomics,
immunomics,
proteomics,
functional
impact,
epigenetic
changes,
metabolomics,
are
enabling
further
refinement
customization
therapy.
Decentralized
potential
improve
access
approaches
for
underserved
minorities.
Evaluation
real‐world
data,
assessment
patient‐reported
outcomes,
use
registry
protocols,
interrogation
exceptional
responders,
exploitation
synthetic
arms
all
contributed
personalized
therapeutic
approaches.
With
greater
1
×
10
12
patterns
alterations
4.5
million
possible
three‐drug
combinations,
deployment
artificial
intelligence/machine
learning
may
be
necessary
optimization
individual
therapy
near
future,
also
permit
discovery
new
treatments
real
time.
Molecular Aspects of Medicine,
Journal Year:
2025,
Volume and Issue:
101, P. 101335 - 101335
Published: Jan. 1, 2025
Renal
cell
carcinoma
(RCC)
is
a
malignant
tumor
with
highly
heterogeneous
and
complex
molecular
mechanisms.
Through
systematic
analysis
of
TCGA,
COSMIC
other
databases,
24
mutated
genes
closely
related
to
RCC
were
screened,
including
VHL,
PBRM1,
BAP1
SETD2,
which
play
key
roles
in
signaling
pathway
transduction,
chromatin
remodeling
DNA
repair.
The
PI3K/AKT/mTOR
particularly
important
the
pathogenesis
RCC.
Mutations
such
as
PIK3CA,
MTOR
PTEN
are
associated
metabolic
abnormalities
proliferation.
Clinically,
mTOR
inhibitors
VEGF-targeted
drugs
have
shown
significant
efficacy
personalized
therapy.
Abnormal
regulation
reprogramming,
especially
glycolysis
glutamine
pathways,
provides
cells
continuous
energy
supply
survival
advantages,
GLS1
promising
results
preclinical
studies.
This
paper
also
explores
potential
immune
checkpoint
combination
targeted
drugs,
well
application
nanotechnology
drug
delivery
In
addition,
unique
mechanisms
revealed
individualized
therapeutic
strategies
explored
for
specific
subtypes
TFE3,
TFEB
rearrangement
type
SDHB
mutant
type.
review
summarizes
common
gene
mutations
their
mechanisms,
emphasizes
diagnosis,
treatment
prognosis,
looks
forward
prospects
multi-pathway
therapy,
immunotherapy
treatment,
providing
theoretical
support
clinical
guidance
new
development.
Advanced Therapeutics,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 6, 2025
Abstract
The
extracellular
matrix
(ECM)
serves
not
only
as
a
structural
scaffold
but
also
an
active
regulator
of
cancer
progression,
profoundly
influencing
tumor
behaviour
and
the
microenvironment
(TME).
This
review
focuses
into
pivotal
role
ECM
alterations
in
facilitating
metastasis
explores
therapeutic
strategies
aimed
at
counteracting
these
changes.
We
analyse
targeted
interventions
against
collagen,
including
approaches
to
inhibit
its
biosynthesis
disrupt
associated
signalling
pathways
critical
for
architecture
cell
migration.
Additionally,
therapies
addressing
hyaluronan
are
reviewed,
highlighting
methods
suppress
synthesis
enzymatic
degrade
it,
thereby
mitigating
tumor‐promoting
effects.
discussion
extends
innovative
modulating
stiffness,
focusing
on
roles
cancer‐associated
fibroblasts
lysyl
oxidases,
which
key
contributors
remodelling
mechanical
signalling.
By
strategically
modifying
components,
aim
enhance
efficacy
existing
treatments,
tackle
resistance
mechanisms,
achieve
more
durable
outcomes.
Insights
from
recent
studies
clinical
trials
highlight
promise
overcoming
treatment
improving
patient
Advancing
our
understanding
biology
leads
development
effective
therapies.
Foods,
Journal Year:
2024,
Volume and Issue:
13(23), P. 3886 - 3886
Published: Dec. 1, 2024
Foodborne
pathogens
are
microorganisms
that
cause
illness
through
contamination,
presenting
significant
risks
to
public
health
and
food
safety.
This
review
explores
the
metabolites
produced
by
these
pathogens,
including
toxins
secondary
metabolites,
their
implications
for
human
health,
particularly
concerning
cancer
risk.
We
examine
various
such
as
Salmonella
sp.,
Campylobacter
Escherichia
coli,
Listeria
monocytogenes,
detailing
specific
of
concern
carcinogenic
mechanisms.
study
discusses
analytical
techniques
detecting
chromatography,
spectrometry,
immunoassays,
along
with
challenges
associated
detection.
covers
effective
control
strategies,
processing
techniques,
sanitation
practices,
regulatory
measures,
emerging
technologies
in
pathogen
control.
manuscript
considers
broader
highlighting
importance
robust
policies,
awareness,
education.
identifies
research
gaps
innovative
approaches,
recommending
advancements
detection
methods,
preventive
policy
improvements
better
manage
foodborne
metabolites.
Deleted Journal,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 6, 2025
Abstract
Artificial
intelligence
(AI)
is
rapidly
advancing,
yet
its
applications
in
radiology
remain
relatively
nascent.
From
a
spatiotemporal
perspective,
this
review
examines
the
forces
driving
AI
development
and
integration
with
medicine
radiology,
particular
focus
on
advancements
addressing
major
diseases
that
significantly
threaten
human
health.
Temporally,
advent
of
foundational
model
architectures,
combined
underlying
drivers
development,
accelerating
progress
interventions
their
practical
applications.
Spatially,
discussion
explores
potential
evolving
methodologies
to
strengthen
interdisciplinary
within
medicine,
emphasizing
four
critical
points
imaging
process,
as
well
application
disease
management,
including
emergence
commercial
products.
Additionally,
current
utilization
deep
learning
reviewed,
future
through
multimodal
foundation
models
Generative
Pre‐trained
Transformer
are
anticipated.
Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
14
Published: Jan. 7, 2025
Cancer's
epigenetic
landscape,
a
labyrinthine
tapestry
of
molecular
modifications,
has
long
captivated
researchers
with
its
profound
influence
on
gene
expression
and
cellular
fate.
This
review
discusses
the
intricate
mechanisms
underlying
cancer
epigenetics,
unraveling
complex
interplay
between
DNA
methylation,
histone
chromatin
remodeling,
non-coding
RNAs.
We
navigate
through
tumultuous
seas
dysregulation,
exploring
how
these
processes
conspire
to
silence
tumor
suppressors
unleash
oncogenic
potential.
The
narrative
pivots
cutting-edge
technologies,
revolutionizing
our
ability
decode
epigenome.
From
granular
insights
single-cell
epigenomics
holistic
view
offered
by
multi-omics
approaches,
we
examine
tools
are
reshaping
understanding
heterogeneity
evolution.
also
highlights
emerging
techniques,
such
as
spatial
long-read
sequencing,
which
promise
unveil
hidden
dimensions
regulation.
Finally,
probed
transformative
potential
CRISPR-based
epigenome
editing
computational
analysis
transmute
raw
data
into
biological
insights.
study
seeks
synthesize
comprehensive
yet
nuanced
contemporary
landscape
future
directions
research.
World Journal of Gastroenterology,
Journal Year:
2025,
Volume and Issue:
31(10)
Published: Feb. 26, 2025
This
article
discusses
the
manuscript
recently
published
in
World
Journal
of
Gastroenterology
,
which
explores
application
deep
learning
models
decision-making
processes
via
wireless
capsule
endoscopy.
Integrating
artificial
intelligence
(AI)
into
gastrointestinal
disease
diagnosis
represents
a
transformative
step
toward
precision
medicine,
enhancing
real-time
accuracy
detecting
multi-category
lesions
at
earlier
stages,
including
small
bowel
and
precancerous
polyps,
ultimately
improving
patient
outcomes.
However,
use
AI
clinical
settings
raises
ethical
considerations
that
extend
beyond
technological
potential.
Issues
privacy,
data
security,
potential
diagnostic
biases
require
careful
attention.
must
prioritize
diverse
representative
datasets
to
mitigate
inequities
ensure
across
populations.
Furthermore,
balancing
with
expertise
is
crucial,
positioning
as
supportive
tool
rather
than
replacement
for
physician
judgment.
Addressing
these
challenges
will
support
responsible
deployment
AI,
through
equitable
contribution
patient-centered
care.
Discover Oncology,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: March 13, 2025
Cancer
remains
a
significant
health
issue,
resulting
in
around
10
million
deaths
per
year,
particularly
developing
nations.
Demographic
changes,
socio-economic
variables,
and
lifestyle
choices
are
responsible
for
the
rise
cancer
cases.
Despite
potential
to
mitigate
adverse
effects
of
by
early
detection
implementation
prevention
methods,
several
nations
have
limited
screening
facilities.
In
oncology,
use
artificial
intelligence
(AI)
represents
transformative
advancement
diagnosis,
prognosis,
treatment.
The
AI
biomarker
discovery
improves
precision
medicine
uncovering
signatures
that
essential
treatment
diseases
within
vast
diverse
datasets.
Deep
learning
machine
diagnostics
two
examples
technologies
changing
way
biomarkers
made
finding
patterns
large
datasets
making
new
make
it
possible
deliver
accurate
effective
therapies.
Existing
gaps
include
data
quality,
algorithmic
transparency,
ethical
concerns
privacy,
among
others.
methodologies
with
seeks
transform
improving
patient
survival
rates
through
enhanced
diagnosis
targeted
therapy.
This
commentary
aims
clarify
how
is
identification
novel
optimal
focused
treatment,
improved
clinical
outcomes,
while
also
addressing
certain
obstacles
issues
related
application
oncology.
Data
from
reputable
scientific
databases
such
as
PubMed,
Scopus,
ScienceDirect
were
utilized.
